Adrenergic blocking and cardiovascular effects of a new N-substituted tetrahydroisoquinoline (NC 7197).
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects*; D003714:Denervation; D004285:Dogs; D006339:Heart Rate / Q000187:drug effects; D006584:Hexamethonium Compounds / Q000494:pharmacology; D006614:Hindlimb / Q000294:innervation; D007546:Isoquinolines / Q000494:pharmacology*; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D010477:Perfusion; D010643:Phenoxybenzamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011941:Receptors, Adrenergic / Q000187:drug effects; D011955:Receptors, Drug; D012110:Reserpine / Q000494:pharmacology; D013565:Sympatholytics / Q000494:pharmacology*
D000317:Adrenergic alpha-Antagonists; D006584:Hexamethonium Compounds; D007546:Isoquinolines; D011941:Receptors, Adrenergic; D011955:Receptors, Drug; D013565:Sympatholytics; D010643:Phenoxybenzamine; D012110:Reserpine; D011433:Propranolol; D009638:Norepinephrine